Parkinson‘s Disorder: Taking a Step towards Homogenizing Machine Learning and Medical Science
DOI:
https://doi.org/10.61841/a12s6666Keywords:
Parkinson’s Disorder,, Machine Learning, euro Degeneration,, N Dopamine.Abstract
Machine learning is a scientific endeavor that has grown out of the need for analyzing and processing large scores of data. It aims towards inculcating the ability to learn within computer systems, thereby inciting a curiosity amongst science enthusiasts to explore the newly emerging field of technology. With machine learning being extensively used in everyday tasks, researchers are finding new ways of incorporating the technology in medical sciences, especially in neurodegenerative diseases like Parkinson’s disease. Parkinson’s is a major neurodegenerative disorder which is caused due to the dopamine deficit that occurs in the striatum part of the brain. It is the most sought-after disease in the field of neurological science due to its impact on a larger stratum of the world population. Therefore, the emergence of machine learning approaches to resolving the problems in the detection and treatment of this disease is a breakthrough in the field of clinical care. This review aims to analyze the less explored areas of treatment and diagnosis of PD. It addresses and evaluates the currently used computer-based modeling techniques and algorithms for the diagnosis of PD and emphasizes on specific aspects of treatment using machine learning. Hence, this review aims to unearth the gap between the recent works and the work that further needs to be done in the ambit of Parkinson’s disease.
Downloads
References
[1] Kunwar, A. and K. I. Priyadarsini, "Curcumin and its role in chronic diseases", ‗Anti-inflammatory Nutraceuticals and Chronic Diseases‘, ‘Advances in Experimental Medicine and Biology’, Springer, Cham, vol. 928, pp. 1-25, 2016.
[2] Gitler, Aaron D., Paraminder Dhillon and James Shorter, "Neurodegenerative disease: models, mechanisms, and a new hope", ‘Disease Models & Mechanisms’, vol. 10, pp. 499-502, 2017.
[3] Zlotnik, Alexander, Juan M. Montero, Rubén San-Segundo and Ascensión Gallardo-Antolín, "Random forest-based prediction of Parkinson's disease progression using acoustic, ASR and intelligibility features" In the proceedings of ‘Sixteenth Annual Conference of the International Speech Communication Association’, Interspeech, Dresden, Germany, pp. 503-507, 2015.
[4] Brooks, David J. and Nicola Pavese, "Imaging biomarkers in Parkinson's disease", ‘Progress in neurobiology’, vol. 95, no. 4, pp. 614-628, 2011.
[5] Luo ChunYan, Wei Song, Qin Chen, ZhenZhen Zheng, Ke Chen, Bei Cao, Jing Yang, JianPeng Li, XiaoQi Huang, QiYong Gong, Hui-Fang Shang, "Reduced functional connectivity in early-stage drug-naive Parkinson's disease: a resting-state fMRI study", ‘Neurobiology of aging’, vol. 35, no. 2, pp. 431-441, 2014.
[6] Ziegler, Erik, Maud Rouillard, Elodie André, Tim Coolen, Johan Stender, Evelyne Balteau, Christophe Phillips and Gaëtan Garraux, "Mapping track density changes in nigrostriatal and extranigral pathways in Parkinson's disease", ‘Neuroimage’, vol. 99, pp. 498-508, 2014.
[7] Li, Xuesong, Yuhui Xiong, Simin Liu, Rongsong Zhou, Zhangxuan Hu, Yan Tong, Le He, Zhendong Niu, Yu Ma, and Hua Guo, "Predicting the Post-therapy Severity Level (UPDRS-III) of Patients With Parkinson's Disease After Drug Therapy by Using the Dynamic Connectivity Efficiency of fMRI", ‘Frontiers in neurology’, vol. 10, pp. 668, 2019.
[8] APDA, 2020, ―23 Parkinson's Symptoms To Look For‖, APDA. [online] Available at:
<https://www.apdaparkinson.org/what-is-parkinsons/symptoms/#motor> [Accessed 11 April 2020].
[9] Jankovic, Joseph, "Parkinson's disease: clinical features and diagnosis", ‘Journal of Neurology, Neurosurgery & Psychiatry’, vol. 79, no. 4, pp. 368-376, 2008.
[10] Khoo, Tien K., Alison J. Yarnall, Gordon W. Duncan, Shirley Coleman, John T. O'Brien, David J. Brooks, Roger A. Barker and David J. Burn, "The spectrum of nonmotor symptoms in early Parkinson disease", ‘Neurology’, vol. 80, no. 3, pp. 276-281, 2013.
[11] Lang, Anthony E. and Andres M. Lozano, "Parkinson's disease", ‘New England Journal of Medicine’, vol. 339, no. 16, pp. 1130-1143, 1998.
[12] Akram, Harith, Chengyuan Wu, Jonathan Hyam, Thomas Foltynie, Patricia Limousin, Enrico De Vita, Tarek Yousry, Marjan Jahanshahi, Marwan Hariz, Timothy Behrens, John Ashburner and Ludvic Zrinzo, "L-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson's disease", ‘Movement Disorders’, vol. 32, no. 6, pp. 874-883, 2017.
[13] Ruonala, Verneri, Mika P. Tarvainen, Pasi A. Karjalainen, Eero Pekkonen and Saara M. Rissanen, "Autonomic nervous system response to L-dopa in patients with advanced Parkinson's disease", In the proceedings of ‘2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)’, IEEE, Milan, Italy, pp. 6162-6165, 2015.
[14] Zhang, Xi, Lifang He, Kun Chen, Yuan Luo, Jiayu Zhou and Fei Wang, "Multi-view graph convolutional network and its applications on neuroimage analysis for parkinson's disease", In the proceedings of ‗AMIA Annual Symposium Proceedings‘, American Medical Informatics Association, vol. 2018, pp. 1147-1156, 2018.
[15] Cools, Roshan, "Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease", ‘Neuroscience & Biobehavioral Reviews’, vol. 30, no. 1, pp. 1-23, 2006.
[16] Shetty, Sachin and Y. S. Rao, "SVM based machine learning approach to identify Parkinson's disease using gait analysis", In the proceedings of ‘2016 International Conference on Inventive Computation Technologies (ICICT)’, IEEE, Coimbatore, India, pp. 1-5, 2016.
[17] Peng, Bo, Suhong Wang, Zhiyong Zhou, Yan Liu, Baotong Tong, Tao Zhang and Yakang Dai, "A multilevel-ROI-features-based machine learning method for detection of morphometric biomarkers in Parkinson's disease", ‘Neuroscience letters’, vol. 651, pp. 88-94, 2017.
[18] Gu, Si-Chun, Jie Zhou, Qing Ye and Can-Xing Yuan, "Personalized prediction of depression in patients with newly diagnosed Parkinson's disease: A prospective cohort study", ‘Journal of Affective Disorders’, vol. 268, pp. 118-126, 2020.
[19] Nalls, Mike A., Cory Y McLean, Jacqueline Rick, Shirley Eberly, Samantha J Hutten, Katrina Gwinn, Margaret Sutherland, Maria Martinez, Peter Heutink, Nigel M Williams, John Hardy, Thomas Gasser, Alexis Brice, T Ryan Price, Aude Nicolas, Margaux F Keller, Cliona Molony, J Raphael Gibbs, Alice Chen-Plotkin, Eunran Suh, Christopher Letson, Massimo S Fiandaca, Mark Mapstone, Howard J Federoff, Alastair J Noyce, Huw Morris, Vivianna M Van Deerlin, Daniel Weintraub, Cyrus Zabetian, Dena G Hernandez, Suzanne Lesage, Meghan Mullins, Emily Drabant Conley, Carrie A M Northover, Mark Frasier, Ken Marek, Aaron G Day-Williams, David J Stone, John P A Ioannidis and Andrew B Singleton,
―Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study‖, ‘The Lancet Neurology’, vol. 14, no. 10, pp.1002-1009, 2015.
[20] McGuire, Lynne I., Alexander H. Peden, Christina D. Orrú, Jason M. Wilham, Nigel E. Appleford, Gary Mallinson, Mary Andrews, Mark W. Head, Byron Caughey, Robert G. Will, Richard S. G. Knight and Alison J. E. Green, "Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease", ‘Annals of neurology’, vol. 72, no. 2, pp. 278-285, 2012.
[21] Dosenbach, Nico UF, Binyam Nardos, Alexander L. Cohen, Damien A. Fair, Jonathan D. Power, Jessica A. Church, Steven M. Nelson, Gagan S. Wig, Alecia C. Vogel, Christina N. Lessov-Schlaggar, Kelly Anne Barnes, Joseph W. Dubis, Eric Feczko, Rebecca S. Coalson, John R. Pruett, Jr., Deanna M. Barch, Steven
E. Petersen and Bradley L. Schlaggar, "Prediction of individual brain maturity using fMRI", ‘Science’, vol. 329, no. 5997, pp. 1358-1361, 2010.
[22] Nussbaum, Robert L. and Christopher E. Ellis. "Alzheimer's disease and Parkinson's disease", ‗Genomic Medicine, The New England Journal of Medicine’, vol. 348, pp. 1356-1364, 2003.
[23] Tsoulos, Ioannis, Georgia Mitsi, Athanassios Stavrakoudis and M. D. Papapetropoulos, "Application of Machine Learning in a Parkinson's Disease Digital Biomarker Dataset Using Neural Network Construction (NNC) Methodology Discriminates Patient Motor Status", ‘Frontiers in ICT’, vol. 6, no. 10, 2019.
[24] Wingate, James, Ilianna Kollia, Luc Bidaut and Stefanos Kollias, "A Unified Deep Learning Approach for Prediction of Parkinson's Disease", ‗arXiv preprint arXiv:1911.10653‘, 2019.
[25] Ramdhani, Ritesh A., Anahita Khojandi, Oleg Shylo and Brian H. Kopell, "Optimizing clinical assessments in Parkinson's disease through the use of wearable sensors and data driven modeling", ‘Frontiers in computational neuroscience’, vol. 12, no. 72, 2018.
[26] Memedi, Mevludin and Somayeh Aghanavesi, "A partial least-squares regression model to measure Parkinson's disease motor states using smartphone data", In the proceedings of ‘The 53rd Hawaii International Conference on System Sciences’, 2020.
[27] Wilson, Heather, Gennaro Pagano, Tayyabah Yousaf, Sotirios Polychronis, Rosa De Micco, Beniamino Giordano, Flavia Niccolini and Marios Politis, "Predict cognitive decline with clinical markers in Parkinson's disease (PRECODE-1)", ‘Journal of Neural Transmission’, vol. 127, pp. 51-59, 2020.
[28] Aarsland, Dag, Kjeld Andersen, Jan P. Larsen and Anette Lolk, "Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study", ‘Archives of neurology’, vol. 60, no. 3, pp. 387-392, 2003.
[29] Marsh, Laura, William M. McDonald, Jeffrey Cummings, Bernard Ravina and NINDS/NIMH Work Group on Depression and Parkinson's Disease, "Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group", ‘Movement Disorders’, vol. 21, no. 2, pp. 148-158, 2006.
[30] Goetz, Christopher G, "New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease", ‘Movement disorders’, vol. 25, no. S1, pp. S104-S109, 2010.
[31] Braak, Heiko, Kelly Del Tredici, Udo Rüb, Rob AI De Vos, Ernst NH Jansen Steur and Eva Braak, "Staging of brain pathology related to sporadic Parkinson's disease", ‘Neurobiology of aging’, vol. 24, no. 2, pp. 197-211, 2003.
[32] Hoehn, Margaret M. and Melvin D. Yahr, "Parkinsonism: onset, progression, and mortality", ‘Neurology’,
vol. 17, no. 5, pp. 427-442, 1967.
[33] Alexander, Garrett E., Mahlon R. DeLong and Peter L. Strick, "Parallel organization of functionally segregated circuits linking basal ganglia and cortex", ‘Annual review of neuroscience’, vol. 9, pp. 357-381, 1986.
[34] Albin, Roger L., Anne B. Young and John B. Penney, "The functional anatomy of basal ganglia disorders",
‗Perspectives on Disease, Trends in neuroscience’, vol. 12, no. 10, pp. 366-375, 1989.
[35] Alexander, Garrett E. and Michael D. Crutcher, "Functional architecture of basal ganglia circuits: neural substrates of parallel processing", ‘Trends in neurosciences’, vol. 13, no. 7, pp. 266-271, 1990.
[36] Bergman, Hagai, Ariela Feingold, Asaph Nini, Aeyal Raz, Hamutal Slovin, Moshe Abeles and Eilon Vaadia, "Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates", ‘Trends in neurosciences’, vol. 21, no. 1, pp. 32-38, 1998.
[37] Hammond, Constance, Hagai Bergman and Peter Brown, "Pathological synchronization in Parkinson's disease: networks, models and treatments", ‘Trends in neurosciences’, vol. 30, no. 7, pp. 357-364, 2007.
[38] Lalo, Elodie, Stéphane Thobois, Andrew Sharott, Gustavo Polo, Patrick Mertens, Alek Pogosyan and Peter Brown, "Patterns of bidirectional communication between cortex and basal ganglia during movement in patients with Parkinson disease", ‘Journal of Neuroscience’, vol. 28, no. 12, pp. 3008-3016, 2008.
[39] Shimamoto, Shoichi A., Elena S. Ryapolova-Webb, Jill L. Ostrem, Nicholas B. Galifianakis, Kai J. Miller and Philip A. Starr, "Subthalamic nucleus neurons are synchronized to primary motor cortex local field potentials in Parkinson's disease", ‘Journal of Neuroscience’, vol. 33, no. 17, pp. 7220-7233, 2013.
[40] Ted L. Rothstein and C. Warren olanow, ―The neglected side of Parkinson's disease‖, ‘American Scientist’,
vol. 96, no.3, pp. 218-225, 2020.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
